Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• In the 10-mg group, the objective response rate was 40% (97.5% confidence interval (CI), 29 to 52), with 59% of responders maintaining a response for at least 6 months and 55% of these responses ongoing. The 100-mg group had a 32% response rate (97.5% CI, 21 to 44), with 59% maintaining a response for at least 6 months and 57% ongoing.
• Median progression-free survival (PFS) was 4.9 months (95% CI, 2.9 to 6.7) for the 10-mg group and 3.9 months (95% CI, 2.6 to 4.4) for the 100-mg group. Overall survival (OS) estimates at 9 months were 68% for the 10-mg group and 66% for the 100-mg group.
• There were no significant population or subgroup differences reported in terms of effectiveness.
• Cytokine-release syndrome (CRS) occurred in 51% of patients in the 10-mg group and 61% in the 100-mg group, with most cases being grade 1 or 2. Grade 3 CRS was reported in 1% of the 10-mg group and 6% of the 100-mg group.
• Other common adverse events included decreased appetite (29% in the 10-mg group, 44% in the 100-mg group) and pyrexia (35% in the 10-mg group, 33% in the 100-mg group).
• No population types or subgroups information was available in the reviewed studies.